198 related articles for article (PubMed ID: 34950060)
1. Multi-Target Drugs for Blood Cancer in the Elderly: Implications of Damage and Repair in the Cardiovascular Toxicity.
Madonna R
Front Physiol; 2021; 12():792751. PubMed ID: 34950060
[No Abstract] [Full Text] [Related]
2. The role of notch in the cardiovascular system: potential adverse effects of investigational notch inhibitors.
Rizzo P; Mele D; Caliceti C; Pannella M; Fortini C; Clementz AG; Morelli MB; Aquila G; Ameri P; Ferrari R
Front Oncol; 2014; 4():384. PubMed ID: 25629006
[TBL] [Abstract][Full Text] [Related]
3. Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells.
Mozneb M; Jenkins A; Sances S; Pohlman S; Workman MJ; West D; Ondatje B; El-Ghazawi K; Woodbury A; Garcia VJ; Patel S; Arzt M; Dezem F; Laperle AH; Moser VA; Ho R; Yucer N; Plummer J; Barrett RJ; Svendsen CN; Sharma A
Lab Chip; 2024 Feb; 24(4):869-881. PubMed ID: 38252454
[TBL] [Abstract][Full Text] [Related]
4. The Myocyte-Damaging Effects of the BCR-ABL1-Targeted Tyrosine Kinase Inhibitors Increase with Potency and Decrease with Specificity.
Hasinoff BB; Patel D; Wu X
Cardiovasc Toxicol; 2017 Jul; 17(3):297-306. PubMed ID: 27696211
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced cardiac toxicity and adverse drug reactions, a narrative review.
Destere A; Merino D; Lavrut T; Rocher F; Viard D; Drici MD; Gérard AO
Therapie; 2024; 79(2):161-172. PubMed ID: 37957054
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Toxicity of Proteasome Inhibitors in Multiple Myeloma Therapy.
Zheng Y; Huang S; Xie B; Zhang N; Liu Z; Tse G; Liu T
Curr Probl Cardiol; 2023 Mar; 48(3):101536. PubMed ID: 36481392
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib induces cardiac developmental toxicity in zebrafish embryos through regulation of Notch mediated-oxidative stress generation.
Liu J; Huang L; Wan M; Chen G; Su M; Han F; Liu F; Xiong G; Liao X; Lu H; Li W; Cao Z
Environ Toxicol; 2022 Jun; 37(6):1310-1320. PubMed ID: 35119177
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of cardiovascular toxicity by proteasome inhibitors: New paradigm derived from clinical and pre-clinical evidence.
Gavazzoni M; Vizzardi E; Gorga E; Bonadei I; Rossi L; Belotti A; Rossi G; Ribolla R; Metra M; Raddino R
Eur J Pharmacol; 2018 Jun; 828():80-88. PubMed ID: 29550338
[TBL] [Abstract][Full Text] [Related]
9. Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway.
Madonna R; Pieragostino D; Cufaro MC; Doria V; Del Boccio P; Deidda M; Pierdomenico SD; Dessalvi CC; De Caterina R; Mercuro G
J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32197359
[TBL] [Abstract][Full Text] [Related]
10. The two facets of receptor tyrosine kinase in cardiovascular calcification-can tyrosine kinase inhibitors benefit cardiovascular system?
Masbuchin AN; Widodo ; Rohman MS; Liu PY
Front Cardiovasc Med; 2022; 9():986570. PubMed ID: 36237897
[TBL] [Abstract][Full Text] [Related]
11. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond.
Di Lisi D; Madonna R; Zito C; Bronte E; Badalamenti G; Parrella P; Monte I; Tocchetti CG; Russo A; Novo G
Int J Cardiol; 2017 Jan; 227():11-17. PubMed ID: 27866063
[TBL] [Abstract][Full Text] [Related]
12. Computational model of cardiomyocyte apoptosis identifies mechanisms of tyrosine kinase inhibitor-induced cardiotoxicity.
Grabowska ME; Chun B; Moya R; Saucerman JJ
J Mol Cell Cardiol; 2021 Jun; 155():66-77. PubMed ID: 33667419
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S19-26. PubMed ID: 27183521
[TBL] [Abstract][Full Text] [Related]
14. The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review.
Wu Q; Bai B; Tian C; Li D; Yu H; Song B; Li B; Chu X
Cardiovasc Drugs Ther; 2022 Jun; 36(3):511-524. PubMed ID: 33847848
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib and Imatinib Display Differential Cardiotoxicity in Adult Rat Cardiac Fibroblasts That Involves a Role for Calcium/Calmodulin Dependent Protein Kinase II.
McMullen CJ; Chalmers S; Wood R; Cunningham MR; Currie S
Front Cardiovasc Med; 2020; 7():630480. PubMed ID: 33598481
[No Abstract] [Full Text] [Related]
16. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.
Doherty KR; Wappel RL; Talbert DR; Trusk PB; Moran DM; Kramer JW; Brown AM; Shell SA; Bacus S
Toxicol Appl Pharmacol; 2013 Oct; 272(1):245-55. PubMed ID: 23707608
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular toxicity associated with the multitargeted tyrosine kinase inhibitor anlotinib.
Zhao S; Wang P; Yin F; Wu J; Wang Y; Li P; Zhang Y; Yang J; Guo X; Zhang D; Song P
Tumori; 2023 Apr; 109(2):186-196. PubMed ID: 35311404
[TBL] [Abstract][Full Text] [Related]
18. Protein Quality Control Dysfunction in Cardiovascular Complications Induced by Anti-Cancer Drugs.
Fu HY; Mukai M; Awata N; Sakata Y; Hori M; Minamino T
Cardiovasc Drugs Ther; 2017 Feb; 31(1):109-117. PubMed ID: 28120277
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms.
Pantazi D; Tselepis AD
Thromb Res; 2022 May; 213 Suppl 1():S95-S102. PubMed ID: 36210569
[TBL] [Abstract][Full Text] [Related]
20. Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management.
Wu P; Oren O; Gertz MA; Yang EH
Curr Oncol Rep; 2020 Jun; 22(7):66. PubMed ID: 32514632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
